TABLE 1

Baseline demographics according to exacerbation history in the year prior to screening

Subgroup
Single moderateFrequent moderateSevere
Subjects3056 (30)4628 (45)2671 (26)
Age years65.2±7.9565.3±8.4665.4±8.29
Male2069 (68)2922 (63)1879 (70)
White2408 (79)3604 (78)1971 (74)
Former smoker1964 (64)3014 (65)1790 (67)
BMI kg·m−226.10±6.04327.03±5.83326.52±6.532
Lung function post-bronchodilator
 At screening FEV1 L1.046±0.31931.437±0.50361.247±0.5037
 FEV1 % predicted37.0±8.8551.9±14.7744.4±15.25
 FEV1/FVC ratio0.421±0.10280.510±0.11610.458±0.1201
Baseline# concomitant COPD medication at screening alone or in combination
 LAMA243 (8)375 (8)213 (8)
 LABA84 (3)166 (4)41 (2)
 LAMA+LABA327 (11)392 (8)215 (8)
 ICS+LABA906 (30)1694 (37)741 (28)
 ICS+LAMA+LABA1258 (41)1651 (36)1274 (48)
Baseline blood eosinophil counts
203±186230±256232±242
 Patients with count %
  <100262524
  100–300555352
  >300192323

Date are presented as n (%) or mean±sd, unless otherwise stated. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist. #: between day of screening −3 days and date of screening (inclusive).